PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: OcuCure Therapeutics, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

OcuCure Therapeutics Ophthalmic Lead Compound for AMD Demonstrates Robust Efficacy in Primates - OcuCure Therapeutics, Inc., a biopharmaceutical company specializing in the treatment of eye disease, currently under development as a topical eye drop treatment of age-related macular degeneration (AMD) - OcuCure.com
OcuCure Therapeutics Ophthalmic Lead Compound for AMD Demonstrates Robust Efficacy in Primates

 

NewswireToday - /newswire/ - Roanoke, VA, United States, 2009/07/13 - OcuCure Therapeutics, Inc., a biopharmaceutical company specializing in the treatment of eye disease, currently under development as a topical eye drop treatment of age-related macular degeneration (AMD) - OcuCure.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

OcuCure Therapeutics, Inc., a biopharmaceutical company specializing in the treatment of eye disease, reported final results from primate testing of its lead compound OC-10X, currently under development as a topical eye drop treatment of age-related macular degeneration (AMD). Results indicated a 43 percent inhibition of ocular neovascularization in primate eyes treated with OC-10X. The laser-induced choroidal neovascularization (CNV) primate model is considered the gold standard to demonstrate AMD efficacy.

These compelling results follow earlier successful safety and efficacy studies in rabbits and rats. OC-10X demonstrated both antiangiogenic (inhibition) and angiolytic (regression) properties in animal models of AMD when administered as a topical eye drop. OC-10X is also being evaluated for the treatment of diabetic retinopathy (DR).

“This primate efficacy data is very impressive and suggests that OC-10X may have an important role in the management of exudative AMD in humans,” commented Craig M. Greven, MD, Professor and Chairman of the Department of Ophthalmology at Wake Forest University, consulting Chief Medical Officer for OcuCure.

The primate studies were conducted at the Eastern Virginia Medical School T.R. Lee Center for Ocular Pharmacology. CNV was induced (using laser photocoagulation) in both eyes of eight primates followed by intravitreal injection of OC-10X in one eye; the other eye served as the control. Two weeks later, a second injection was administered. Four weeks after the initial laser injury, the areas of CNV lesions were measured. The 43 percent difference between the smaller CNV lesion in the OC-10X treated eyes when compared to the larger lesions in the untreated control eyes was statistically significant (t-test, p=0.025).

“This primate experiment corroborates our previous animal efficacy studies,” stated Patricia B. Williams, PhD, OcuCure’s Chief Scientific Officer. “Most other AMD therapies work at the cell signaling level by inhibiting growth factor effects. In contrast, OC-10X works independently of growth factors and thus could provide better long term visual outcome and overall efficacy,” she added.

This successful primate study follows long-term OC-10X safety studies recently presented at the annual meeting of the Association for Research in Vision and Opthalmology, held in Fort Lauderdale, Fla. After long-term topical administration of six to nine months, no changes in corneal or retinal histology or function were observed. Electroretinogram (ERG) studies showed that retinal function remained normal during this long- term testing. Additionally, complete blood counts, clinical blood chemistry panels, and gross necropsy indicated no evidence of major organ dysfunction.

“We’re encouraged by these findings, because the primate model is a reasonable predictor of human clinical data,” said OcuCure’s President and CEO Sunder Malkani. “Given the robustness of the efficacy and safety data, coupled with the unique properties of OC-10X, OcuCure is an attractive opportunity, with the potential to change the AMD therapeutic landscape.”

About OcuCure

OcuCure Therapeutics (ocucure.com) is a biopharmaceutical company, formed in August 2005 based on initial drug discovery research supported by the Carilion Biomedical Institute. The Company’s lead compound, OC-10X, targets Age-related Macular Degeneration (AMD), the leading cause of blindness in developed countries, and diabetic retinopathy (DR), the leading cause of blindness in the U.S. among adults age 24-70. OcuCure’s management team and Board of Directors are comprised of individuals experienced in creating and growing eye care businesses. Its intellectual property is protected by several U.S. and foreign patent applications. OcuCure has met with the FDA to review current progress, the requirements for clinical trials, and the regulatory pathway.

About Age Related Macular Degeneration (AMD)

AMD is a debilitating eye disease and is the leading cause of legal blindness in developed countries. Nearly one in three people over the age of 65 develop AMD. As the number of elderly people increases, so will the prevalence of AMD. There are two forms of AMD, dry and wet. About 10 to 15 percent of AMD patients develop the wet form. In wet AMD, the growth of new abnormal fragile blood vessels under the retina can lead to rapid vision loss and blindness.

About Diabetic Retinopathy (DR)

Like AMD, diabetic retinopathy is a major cause of blindness in American adults and also is caused by the growth of abnormal blood vessels. These new blood vessels are fragile and may leak fluid and blood into the retina. DR affects up to 80 percent of all diabetics who have had diabetes for 15 years or more. There are no drugs approved for the treatment of DR.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: OcuCure Therapeutics, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


OcuCure Therapeutics Ophthalmic Lead Compound for AMD Demonstrates Robust Efficacy in Primates

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: J Wade - OcuCure.com 
540-344-1106 news[.]ocucure.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any OcuCure Therapeutics, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From OcuCure Therapeutics, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)